| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
E3 ubiquitin ligase (cereblon/CRBN). E3 ligase Ligand 17 hydrochloride is a ligand for E3 ubiquitin ligase that incorporates a Pomalidomide-based cereblon ligand. It can be connected to the ligand for a target protein by a linker to form PROTACs, which induce ubiquitination and degradation of oncogenic proteins.
|
|---|---|
| ln Vitro |
E3 ligase Ligand 17 hydrochloride serves as a building block for PROTAC synthesis. The Pomalidomide-based cereblon ligand enables recruitment of the E3 ubiquitin ligase complex. When conjugated to a target protein ligand via a linker, the resulting PROTAC induces ubiquitination and degradation of the target protein.
|
| ln Vivo |
In vivo, E3 ligase Ligand 17 hydrochloride is not active as a standalone compound; its activity is realized only when incorporated into a complete PROTAC molecule. The resulting PROTAC would be expected to demonstrate target protein degradation and efficacy in animal models of disease.
|
| Enzyme Assay |
E3 ligase Ligand 17 hydrochloride is characterized by its chemical structure and purity rather than enzymatic activity. The cereblon binding affinity of the Pomalidomide-based ligand can be measured using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) with recombinant cereblon protein. Binding affinity (Kd) is calculated from binding isotherms.
|
| Cell Assay |
Cells are treated with a complete PROTAC molecule synthesized using E3 ligase Ligand 17 hydrochloride. Target protein degradation is assessed by Western blotting. Ubiquitination is evaluated by immunoprecipitation followed by ubiquitin blotting. Functional assays (cell viability, proliferation, apoptosis) are performed to assess the biological effects of target degradation.
|
| Animal Protocol |
Animal studies are conducted with complete PROTAC molecules incorporating E3 ligase Ligand 17 hydrochloride. Mice bearing tumor xenografts or other disease models are administered the PROTAC via appropriate routes. Target protein degradation in tissues is assessed by Western blotting or immunohistochemistry. Efficacy is determined by disease outcome measures.
|
| ADME/Pharmacokinetics |
E3 ligase Ligand 17 hydrochloride has a molecular weight of 352.77 g/mol and formula C1₅H1₇ClN4O4. As a linker-ligand conjugate, its PK properties are determined by the complete PROTAC molecule rather than the building block alone. The compound is a light yellow to yellow solid powder and handled as a research chemical.
|
| Toxicity/Toxicokinetics |
Toxicology data for E3 ligase Ligand 17 hydrochloride are not publicly available. As a building block for PROTACs, toxicity would be assessed for the final PROTAC molecule. Standard preclinical safety assessment would include cytotoxicity screening, hERG testing, and repeat-dose toxicology studies in rodents.
|
| References | |
| Additional Infomation |
E3 ligase Ligand 17 hydrochloride is a research reagent for PROTAC development. It is not clinically approved. The compound incorporates a Pomalidomide-based cereblon ligand and serves as a crucial building block for designing targeted protein degraders using PROTAC technology.
|
| Molecular Formula |
C15H17CLN4O4
|
|---|---|
| Molecular Weight |
352.7729
|
| Exact Mass |
352.093
|
| CAS # |
2305369-00-8
|
| PubChem CID |
139035073
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
550
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl[H].O=C1C2C(=C([H])C([H])=C([H])C=2C(N1C1([H])C(N([H])C(C([H])([H])C1([H])[H])=O)=O)=O)N([H])C([H])([H])C([H])([H])N([H])[H]
|
| InChi Key |
DSJCOXQYDMWPEY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H16N4O4.ClH/c16-6-7-17-9-3-1-2-8-12(9)15(23)19(14(8)22)10-4-5-11(20)18-13(10)21;/h1-3,10,17H,4-7,16H2,(H,18,20,21);1H
|
| Chemical Name |
4-(2-aminoethylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~354.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8347 mL | 14.1735 mL | 28.3471 mL | |
| 5 mM | 0.5669 mL | 2.8347 mL | 5.6694 mL | |
| 10 mM | 0.2835 mL | 1.4174 mL | 2.8347 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
